PsychoGenics revolutionized CNS drug discovery with its AI-driven, high-throughput phenotypic platform, SmartCube©, which uses deep learning to obtain profiles of known and novel drugs to predict therapeutic potential. We have an extensive pipeline of partnered and internal programs, the most advanced of which, SEP-856, developed in collaboration with Sunovion, is in a Phase III clinical trial. SEP-856 was recently awarded Breakthrough Therapy Designation for Schizophrenia, with a novel mechanism of action, improvement of both positive and negative symptoms, and with fewer or no side effects.

Team Members

Varney headshot

Mark Varney, PhD

Chief Scientific Officer


Daniela Brunner, PhD

Chief Innovation Officer


Maxson Jarecki

Sales and Marketing Associate